RxDoctor Payments Data

Stephen Moll, MD

Family Medicine · Salina, KSNPI 1609369008

Payments from drug & device makers

$410in general payments, 2019–2025

Across 18 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Geron Corporation$117
  • AbbVie$90
  • Novo Nordisk$75
  • Lilly USA, LLC$33
  • Amgen$30
  • Sanofi Pasteur Inc.$19
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$410 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$12,992
Medicare patients
89
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$39,304
JardianceEmpagliflozin30$33,148
OzempicSemaglutide25$24,446
TrulicityDulaglutide16$15,729
XareltoRivaroxaban34$15,140
FarxigaDapagliflozin Propanediol17$10,021
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,407
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$5,328
Fentanyl41$4,453
Advair HfaFluticasone Propion/Salmeterol12$3,738
MyrbetriqMirabegron14$3,145
Levothyroxine Sodium139$1,732
Losartan Potassium112$1,462
Atorvastatin Calcium151$1,220
Gabapentin100$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$39,30459 claims
Boehringer IngelheimJardiance$15$33,14830 claims
Novo NordiskOzempic$75$24,44625 claims
Lilly USA, LLCTrulicity$33$15,72916 claims
AstraZenecaFarxiga$15$10,02117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Salina

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →